Pathologic aortic dilation — AAA usually infrarenal and degenerative; thoracic often connective tissue or bicuspid-related; surgical thresholds drive management.
Also known as: AAA, abdominal aortic aneurysm, TAA, thoracic aortic aneurysm, aortic aneurysm
Overview
Localized dilation of the aorta to ≥1.5 times the expected normal diameter. Abdominal aortic aneurysm (AAA): infrarenal aorta ≥3.0 cm. Thoracic aortic aneurysm (TAA): ascending ≥4.5 cm or descending ≥4.0 cm in adults (varies by body surface area).
Epidemiology
AAA prevalence ~5-9% in men >65; rare in women. Strong association with smoking. TAA less common; bicuspid aortic valve and connective tissue disease drive ascending TAA in younger patients.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Aortic Aneurysm (Abdominal and Thoracic) outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Loss of medial elastin and smooth muscle, with collagen disorganization, weakens the aortic wall. Wall tension increases with diameter (Laplace's law), driving further dilation and eventual rupture. Connective tissue diseases produce structurally abnormal extracellular matrix; atherosclerosis drives the degenerative AAA phenotype.
Clinical presentation
Symptoms
Most aneurysms are asymptomatic — detected on screening or incidentally
AAA expansion or impending rupture: vague abdominal or back pain, flank pain
Acute pancreatitis — Epigastric pain radiating to back with elevated lipase
MI (inferior wall) — Especially in older patients with epigastric or back pain; ECG and troponin
Diagnostic workup
Diagnostic criteria
AAA: infrarenal aortic diameter ≥3.0 cm. Surgical repair thresholds — AAA: ≥5.5 cm in men, ≥5.0 cm in women, expansion >0.5 cm in 6 months, or symptomatic. Ascending TAA: ≥5.5 cm (≥5.0 cm Marfan or bicuspid with risk factors, ≥4.5 cm Loeys-Dietz or undergoing AVR). Descending TAA: ≥5.5-6.0 cm or rapid expansion.
Abdominal ultrasound — screening modality of choice for AAA (USPSTF recommends one-time screening for men 65-75 who ever smoked)
CT angiography — definitive sizing, anatomy, planning for endovascular repair
MR angiography — alternative when iodinated contrast contraindicated
Echocardiography for ascending TAA and aortic valve assessment
Chest CT with contrast for thoracic aneurysm sizing and surveillance
Diagnostic algorithm
AAA size
Surveillance
Action
<3.0 cm
None (or single rescreen at 65-75 if ever smoker)
No further imaging
3.0-3.9 cm
Ultrasound every 3 years
Risk factor modification
4.0-4.9 cm
Ultrasound every 12 months
Risk factor modification, smoking cessation
5.0-5.4 cm
Ultrasound every 6 months
Vascular surgery referral; repair women ≥5.0 cm
≥5.5 cm or rapid growth or symptomatic
Pre-op CTA
Elective repair (EVAR or open)
Surveillance and surgical thresholds for abdominal aortic aneurysm.
Treatment
First-line
Smoking cessation (single most effective intervention to slow AAA growth)
Blood pressure control — beta-blocker (metoprolol, atenolol) reduces aortic wall stress; ARB (losartan) has shown benefit in Marfan (additive to beta-blocker)
High-intensity statin therapy
Surveillance imaging by size:
• AAA 3.0-3.9 cm: ultrasound every 3 years
• AAA 4.0-4.9 cm: ultrasound every 12 months
• AAA 5.0-5.4 cm: ultrasound every 6 months
Manage cardiovascular risk factors (treat as CAD risk equivalent)
Second-line / adjunct
Elective AAA repair — open surgical or endovascular aneurysm repair (EVAR) at ≥5.5 cm men, ≥5.0 cm women, rapid expansion, symptomatic, or rupture
EVAR — lower perioperative mortality and faster recovery but higher reintervention rate; favored when anatomy permits and in higher-risk patients
Open repair — durable, fewer late reinterventions; preferred in younger patients with long life expectancy or unsuitable EVAR anatomy
Thoracic endovascular aortic repair (TEVAR) for descending TAA at threshold or complicated by rupture/penetrating ulcer
Open ascending aortic / root replacement — surgical repair with valve-sparing or composite graft (Bentall) for ascending TAA
Emergency repair for symptomatic or ruptured aneurysm regardless of size
Complications
Rupture and exsanguination (mortality >50% even with surgery)
Aortic dissection
Distal embolization, limb ischemia
Aortoenteric fistula (especially post-graft)
Endoleak after EVAR (types I-V; surveillance imaging required)
Renal/spinal cord ischemia from suprarenal or thoracoabdominal repairs
PANCE pearls
USPSTF recommends one-time AAA screening with abdominal ultrasound in men 65-75 who have ever smoked.
AAAs grow ~0.3-0.5 cm/year on average; rapid expansion (>1 cm/year) is an indication for repair regardless of absolute diameter.
Triad of hypotension, back pain, and pulsatile abdominal mass = ruptured AAA — to the OR, not to CT if unstable.
Marfan syndrome: repair ascending aorta at ≥5.0 cm (or 4.5 cm with high-risk features) — lower threshold than degenerative TAA.
Always check for an aortoenteric fistula in a patient with prior aortic graft and a herald GI bleed — uncontrolled exsanguination follows.
References
SVS 2018 AAA — The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm (Chaikof et al., J Vasc Surg 2018)
ACC/AHA 2022 Aortic Disease — 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease (Isselbacher et al., JACC 2022)
USPSTF 2019 — Screening for Abdominal Aortic Aneurysm: US Preventive Services Task Force Recommendation Statement (JAMA 2019)
EVAR-1 — Endovascular versus Open Repair of Abdominal Aortic Aneurysm (United Kingdom EVAR Trial Investigators, NEJM 2010)
Practice Cardiovascular questions on FirstPassPA
Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.